Sign in
Enrolling by invitationNo phase

Visual Outcomes in Patients Contralaterally Implanted With PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro

Key facts

Who runs it
Brian Shafer
Where
Alexandria, Bala-Cynwyd, Baltimore, Bozeman, and Plymouth Meeting, United StatesSee the 5 sites
Trial code
Status
Enrolling by invitation
People taking part
346 people, planned
Started
5 Aug 2025
Expected to end
1 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Clareon PanOptix Pro and Clareon Vivity Intraocular Lens
  • Clareon PanOptix Pro Intraocular Lenses
Record updated
22 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Bilateral diagnosis of age-related cataracts
  • Planned bilateral cataract removal by phacoemulsification with either:
  • Contralateral implantation of Clareon PanOptix Pro/PanOptix Pro Toric in one eye and Clareon Vivity/Vivity Toric in the fellow eye, or
  • Bilateral implantation of Clareon PanOptix Pro/PanOptix Pro Toric
  • Expected best monocular corrected distance visual acuity (BCDVA) of 0.1 logMAR (Snellen 20/25) or better in both eyes postoperatively, as determined by the surgeon
  • Residual astigmatism expected to be ≤0.50 diopters in both eyes postoperatively (using toric IOLs or arcuate incisions as needed)
  • Normal ocular findings aside from cataracts

Who cannot take part

  • Previous history of any ocular surgery, including corneal refractive surgery
  • Any planned simultaneous or combined procedures at the time of cataract surgery (e.g., MIGS)
  • Preexisting macular disease or other retinal degenerative disease expected to cause vision loss
  • Severe dry eye disease
  • Any condition (in the investigator's opinion) that may affect study endpoints
  • History of amblyopia or monofixation syndrome with poor stereoscopic vision
  • Any active ocular infection or inflammation
  • Glaucoma
  • Nystagmus or strabismus
  • Zonular laxity or dehiscence, pseudoexfoliation
  • Subjects desiring monovision
  • Total corneal higher-order aberrations (HOA) greater than 0.6 microns
  • Participation in another clinical study that could interfere with study results
  • Pregnant, breastfeeding, or planning to become pregnant during the study (as determined by verbal inquiry)

Where in United States

  • Vance Thompson VisionAlexandria, United StatesEnrolling by invitation
  • Main Line Surgery CenterBala-Cynwyd, United StatesEnrolling by invitation
  • VIP Eye CareBaltimore, United StatesEnrolling by invitation
  • Vance Thompson VisionBozeman, United StatesEnrolling by invitation
  • Shafer Vision InstitutePlymouth Meeting, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

Title:

Read full original descriptionShow less

Visual Outcomes in Patients Contralaterally Implanted with PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro

Sponsor:

Brian Shafer, MD, Shafer Vision Institute

Objective:

To compare visual outcomes and patient-reported satisfaction in cataract patients receiving either:

Contralateral implantation (PanOptix Pro in one eye, Clareon Vivity in the other)

Bilateral PanOptix Pro implants

Key hypotheses:

Contralateral implantation is non-inferior for binocular best-corrected distance visual acuity (BCDVA) at 4 m.

Contralateral implantation yields superior visual disturbance outcomes (less halo, glare, starburst).

Design:

Prospective, randomized, double-masked, two-arm, multicenter study

N = 346 subjects (173 per arm)

5 surgeons across 4 sites

All patients undergo bilateral phacoemulsification aiming for emmetropia

Randomized 1:1 to:

Arm 1: PanOptix Pro (dominant eye) + Clareon Vivity (non-dominant eye)

Arm 2: Bilateral PanOptix Pro

Surgical Details:

Femtosecond laser optional

Second eye surgery ≤4 weeks after first

Toric IOLs or arcuate incisions for residual astigmatism ≤0.50 D

Biometry with ARGOS, IOLMaster 700, or Lenstar

Toric alignment with ORA, Callisto, etc.

Assessments:

Visual acuity at 4 m, 66 cm, 40 cm, 33 cm in photopic and mesopic conditions

Defocus curves, contrast sensitivity (with/without glare)

Manifest refraction

Patient-reported outcomes via IOLSAT and QUVID questionnaires

Masking: subjects and assessors unaware of IOL assignments

Endpoints (at 3 months):

Primary: Binocular BCDVA (4 m)

Secondary: DCIVA, DCNVA, UDVA, UIVA, UNVA, defocus curves, refractive outcomes, visual disturbance scores

Exploratory: Mesopic VA, low contrast VA, contrast sensitivity, satisfaction scores

Eligibility Criteria:

Adults with bilateral age-related cataracts

Plan for bilateral phacoemulsification

Expected postop monocular BCDVA ≤0.1 logMAR (20/25)

Residual astigmatism ≤0.50 D

Exclusions include corneal pathology, macular disease, glaucoma, prior ocular surgery, amblyopia, severe dry eye, high HOA (>0.6 um), monovision preference, active infection/inflammation, pregnancy

Statistics:

Non-inferiority margin: 0.1 logMAR

Superiority testing for visual disturbances

Step-down testing hierarchy for primary and secondary outcomes

Sample size powered for 80% at α=0.05, accounting for 10% dropout

Two-proportion Z-tests for dysphotopsia rates

Safety Monitoring:

Adverse Events (AEs) and Serious Adverse Events (SAEs) captured

Definitions, severity grading, and reporting procedures specified

Protocol deviations documented and reported per IRB requirements

Data Handling:

Data anonymized via subject numbers

Stored securely (locked cabinets, password-protected systems)

Study registered at ClinicalTrials.gov

Visit Schedule:

Screening: Consent, eligibility, history

1st \& 2nd Eye Surgery Visits

3-Month Post-Op Visit: Comprehensive visual assessments, questionnaires, AE review

The 2 groups in the trial

  • Contralateral PanOptix Pro and Clareon VivityTreatment being tested

    Subjects randomized to this arm will receive bilateral cataract surgery with contralateral implantation: Alcon Clareon PanOptix Pro or PanOptix Pro Toric IOL in one eye and Alcon Clareon Vivity or Vivity Toric IOL in the fellow eye. The Vivity IOL will be implanted in the dominant eye, with all surgeries targeting emmetropia. Residual astigmatism will be managed to ≤0.50 diopters using toric IOLs or arcuate incisions as needed.

    Treatment: Clareon PanOptix Pro and Clareon Vivity Intraocular Lens

  • Bilateral PanOptix ProExisting treatment, for comparison

    Subjects randomized to this arm will receive bilateral cataract surgery with implantation of Alcon Clareon PanOptix Pro or PanOptix Pro Toric IOLs in both eyes. All eyes will be targeted for emmetropia, and residual astigmatism will be controlled to ≤0.50 diopters using toric IOLs or arcuate incisions as appropriate.

    Treatment: Clareon PanOptix Pro Intraocular Lenses

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
22 September 2025